Physician profile
Jin Wang
NPI 1154353126
$1,338.14
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $65.31 · 2021: $350 · 2022: $309 · 2023: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $355.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $218.93 | 2020-2023 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $158.55 | 2019-2023 | Auryxia |
| Vifor Pharma, INC. | $140.67 | 2021-2023 | Korsuva, Veltassa |
| Otsuka America Pharmaceutical, INC. | $115.74 | 2019 | |
| Cardiovascular Systems INC. | $107.98 | 2019 | |
| Fresenius USA Marketing, INC. | $105.02 | 2020-2022 | |
| Glaxosmithkline, LLC. | $81.09 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $56.63 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $48.24 | 2021 | |
| Amgen INC. | $48.17 | 2022 | |
| Aurinia Pharma U.S., INC. | $47.11 | 2023 | Lupkynis |
| Calliditas Therapeutics US INC. | $45.36 | 2022-2023 | Tarpeyo |
| Travere Therapeutics, INC. | $44.88 | 2023 | |
| Novo Nordisk INC | $24.85 | 2023 | Rybelsus, Ozempic |
| Horizon Therapeutics Plc | $23.08 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $23.08 | 2022 | |
| Viiv Healthcare Company | $16.59 | 2023 | Cabenuva |
| Alnylam Pharmaceuticals INC. | $16.17 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jin Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.